Kimberly Stegmaier was named chair of Pediatric Oncology at Dana-Farber Cancer Institute and associate chief of the Division of Hematology/Oncology at Boston Children’s Hospital. Her appointment is effective April 1.
Leon Bernal-Mizrachi was appointed the inaugural chair of the Department of Cancer Medicine in the Wake Forest University School of Medicine at Atrium Health Wake Forest Baptist, effective April 1.Â
Matthew E. BurowJessica ShankZachary PursellMatthew E. Burow, Jessica Shank, and Zachary Pursell were appointed to the leadership team of Tulane Cancer Center.
Ze’ev Ronai, a cancer investigator and director of the Translational Research Institute at Cedars-Sinai, received an Outstanding Investigator Award from NCI.Â
Jason A. DamskerMichael NoonanJason A. Damsker was appointed professor in the Department of Hematology/Oncology and Michael Noonan was appointed assistant professor in the Supportive Oncology and Palliative Care Program at Fox Chase Cancer Center.Â
 Samuel AchilefuJennifer CochranDorin ComaniciuThe National Academy of Engineering elected three cancer researchers—Samuel Achilefu, Jennifer Cochran, Dorin Comaniciu—to its class of 2025, among 128 members and 22 international members.
The governing body of the Cancer Prevention and Research Institute of Texas approved 53 grants totaling more than $67 million to state research institutions to advance the state’s fight against cancer. The grants provide funding for a wide array of cancer projects, including CPRIT Scholar recruitment awards, funding for collaborative core facilities, and support for cancer clinical trials.
Cedars-Sinai performed the first robot-assisted microsurgical head-and-neck cancer reconstructive surgery in the United States after the robot device received FDA approval for the procedure.
A study presented by researchers at Fox Chase Cancer Center shows that some patients with metastatic kidney cancer receiving a combination therapy can safely stop or pause treatment after two years if they have a good response.
Bristol Myers Squibb announced the final analysis of overall survival from the phase III CheckMate-816 study, which evaluated Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer.Â
